Contrast enhancement of central nervous system lesions: Multicenter intraindividual crossover comparative study of two MR contrast agents

Radiology

Volumn 240, Issue 2, 2006, Pages 389-400

  Maravilla, Kenneth R ^a   Maldjian, Joseph A ^b   Schmalfuss, Ilona M ^c   Kuhn, Matthew J ^d   Bowen, Brian C ^e   Wippold II, Franz J ^f   Runge, Val M ^g   Knopp, Michael V ^h   Kremer, Stephane ⁱ   Wolansky, Leo J ^j   Anzalone, Nicoletta ^k   Essig, Marco ^l   Gustafsson, Lars ^m  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j University of Medicine and Dentistry of New Jersey   (United States)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADULT; AGED; ARACHNOIDITIS; BOLUS INJECTION; BRAIN CANCER; BRAIN PSEUDOTUMOR; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR MALFORMATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; EPISTAXIS; FEMALE; GLIOMA; GOOD CLINICAL PRACTICE; HUMAN; HYPOPHYSIS ADENOMA; IMAGE ANALYSIS; INFORMED CONSENT; INJECTION; MALE; MENINGIOMA; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUANTITATIVE DIAGNOSIS; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SARCOIDOSIS; SQUAMOUS CELL CARCINOMA; STANDARD; UNITED STATES; WILCOXON SIGNED RANKS TEST;

EID: 33746224273     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2402051266     Document Type: Article

References (58)

1. Stack JP, Antoun NM, Jenkins JP, Metcalfe R, Isherwood I. Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain. Neuroradiology 1988;30:145-154.
2. Hesselink JR, Healy ME, Press GA, Brahme FJ. Benefits of Gd-DTPA for MR imaging of intracranial abnormalities. J Comput Assist Tomogr 1988;12:266-274.
3. Elster AD, Moody DM, Ball MR, Laster DW. Is Gd-DTPA required for routine cranial MR imaging? Radiology 1989;173:231-238.
4. Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neororadiol 1990;11:785-791.
5. Sze G. New applications of MR contrast agents in neuroradiology. Neuroradiology 1990;32:421-438.
6. Davis PC, Hudgins PA, Peterman SB, Hoffman JCJ. Diagnosis of cerebral metastases: double-dose delayed CT vs. contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991;12:293-300.
7. Atlas SW. Rationale and clinical indications for contrast agents in MR imaging of the brain and spine. J Comput Assist Tomogr 1993;17(suppl 1):S1-S7.
8. Wolf GL, Walsh SJ, McNeil BJ. Utility of magnetic resonance contrast agents in routine cranial imaging: case study of an evaluative method. Neuroimaging Clin N Am 1994;4:55-62.
9. Tas MW, Barkhol F, van Walderveen MA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259-264.
10. Runge VM, Muroff LR, Wells JW. Principles of contrast enhancement in the evaluation of brain diseases: an overview. J Magn Reson Imaging 1997;7:5-13.
11. Sze GK. Clinical experience with gadolinium contrast agents in spinal MR imaging. J Comput Assist Tomogr 1993;17(suppl 1):S8-S13.
12. Bradley WG. Use of gadolinium chelates in MR imaging of the spine. J Magn Reson Imaging 1997;7:38-46.
13. Colosimo C, Manfredi R, Tartaglione T. Contrast enhancement issues in the MR evaluation of the central nervous system. Eur Radiol 1997;7(suppl 5):231-237.
14. Runge VM, Muroff LR, Jinkins JR. Central nervous system: review of clinical use of contrast media. Top Magn Reson Imaging 2001;12:231-263.
15. Maravilla KR. Optimal use of MR contrast agents: how much is enough? AJNR Am J Neuroradiol 1991;12:881-883.
16. Mathews VP, Caldemeyer KS, (Ulmer JL, Nguyen H, Yuh WT. Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions. J Magn Reson Imaging 1997;7:14-22.
17. Yuh WT, Maley JE. Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin N Am 1998;6:113-124.
18. Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995;16:373-380.
19. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol 1992;13:1199-1206.
20. Haustein J, Laniado M, Niendorf HP, et al. Triple dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993;186:855-860.
21. Yuh WT, Halloran JI, Mayr NA, Fisher DJ, Nguyen HD, Simonson TM. Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 1994;4:243-249.
22. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging 1994;4:669-673.
23. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994;15:1037-1051.
24. Yuh WT, Nguyen HD, Tali ET, et al. Delineation of gliomas with various doses of MR contrast material. AJNR Am J Neuroradiol 1994;15:983-989.
25. Yuh WT, Halloran JI, Mayr NA, Fisher DJ, Simonson TM, Nguyen HD. Gadolinium contrast dose in the evaluation of central nervous system tumors. Neuroimaging Clin N Am 1994;4:81-88.
26. Yuh WT, Parker JR, Carvlin MJ. Indication-related dosing for magnetic resonance contrast media. Eur Radiol 1997;7(suppl 5):269-275.
27. Okubo T, Hayashi N, Shirouzu I, et al. Detection of brain metastasis: comparison of Turbo-FLAIR imaging, T2-weighted imaging and double-dose gadolinium-enhanced MR imaging. Radiat Med 1998;16:273-281.
28. Filippi M, Rovaris M, Capra R, et al. A multicentre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 1998;121:2011-2020.
29. Mayr NA, Yuh WT, Millionen MG, et al. Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 1994;15:1053-1061.
30. Black WC. High-dose MR in the evaluation of brain metastases: will increased detection decrease cost? AJNR Am J Neuroradiol 1994;15:1062-1064.
31. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
32. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1):S161-S168.
33. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001;36:72-81.
34. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
35. Colosimo C, Knopp MV, Barreau X, et al. Is increased relaxivity beneficial for contrast-enhanced MR imaging of brain tumors? blinded intraindividual comparison of gadobenate dimeglumine and Gd-DOTA. Neuroradiology 2004;46:655-665.
36. Criteria committee of the American Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. New York, NY: Little, Brown, 1994.
37. Fleiss JL. The design and analysis of clinical experiments. New York, NY: Wiley, 1999.
38. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York, NY: Wiley, 1981.
39. Brugières P, Gaston A, Degryse HR, et al. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 1994;36:27-30.
40. Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75-78.
41. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485-491.
42. Valk J, Algra PR, Hazenberg CJ, Slooff WB, Slavand MG. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 1993;35:173-177.
43. Åkeson P, Jonsson E, Haugen I, Holtas S. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995;37:229-233.
44. Grossman RI, Rubin DI, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000;35:412-419.
45. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 2001;36:65-71.
46. Runge VM, Parker JB, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002;37:269-280.
47. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 2002;37:706-715.
48. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 2003;17:694-702.
49. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2005;234:399-408.
50. Schneider G, Maas R, Schnitze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003;38:85-94.
51. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology 2005;237:45-56.
52. Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT. Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001;45:457-463.
53. Ruscalleda J, Kirchin MA, La Noce A, Pirovano G, Spinazzi A. MultiHance in the assessment of intracranial tumors: results of phase II clinical studies. J Comput Assist Tomogr 1999;23(suppl 1):S19-S27.
54. Johnson PC, Hunt SJ, Drayer BP. Human cerebral gliomas: correlation of postmortem MR findings and neuropathologic findings. Radiology 1989;170:211-217.
55. Giese A, Westphal M. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol 2001;127:217-225.
56. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001;14:525-539.
57. Balériaux D, Colosimo C, Ruscalleda J, et al. Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 2002;44:191-203.
58. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist) and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41(3):213-221.